SCIENCE-BASED WORLD-CLASS SUPPLEMENTS

Which positive outcomes were confirmed for AstaReal®?

• Children’s digital eye strain study (2025, RDBPC):
  A 20% greater reduction in chronic digital eye symptoms was observed compared to the placebo group. Improvements were also detected in eye accommodation ability (stereovision) and pupillary reflexes.
• Muscle soreness study (Barker et al., 2023, RDBPC):
  The astaxanthin group experienced 58% less muscle soreness (DOMS) 24 hours after intense exercise and 32% less soreness 48 hours after exercise compared to placebo.
• Heart rate study (Wika et al., 2023, RDBPC):
  In overweight participants, exercise heart rate was reduced by an average of 7%, while carbohydrate oxidation decreased, helping the body utilize fat more efficiently during physical activity.
• Glucose metabolism study (Urakaze et al., 2021, RCT):
  A positive correlation was identified between increased adiponectin levels (a hormone involved in blood glucose regulation) and reduced LDL cholesterol oxidation.

Summary

All of the studies mentioned above were evaluated as successful (positive) by both the manufacturer and independent researchers, as they demonstrated the effectiveness of the compound in achieving their primary objectives, including reducing muscle soreness, alleviating eye fatigue, and optimizing heart rate response during exercise.

Pharmacokinetic Clinical Human Study (Highest Bioavailability)

Bioavailability and Absorption Study

A peer-reviewed clinical study demonstrated the direct superiority of BioBerb® compared to standard berberine. A single low dose (188 mg) of BioBerb® achieved a record total berberine plasma concentration of 801 ng/mL.

Therefore: BioBerb® offers up to 3 times higher bioavailability than conventional berberine products, enabling beneficial effects at significantly lower dosages while drastically minimizing gastrointestinal side effects (diarrhea, gas, cramps, and related digestive discomfort), which are common drawbacks of standard berberine due to its poor absorption.

Transferable RDBPC and RCT Metabolic Health Studies

Because BioBerb® efficiently delivers berberine into cells, its functional mechanism of action — particularly AMPK enzyme activation — is supported by extensive clinical berberine research.

• Blood sugar and glucose control (RDBPC):
  RDBPC studies on berberine in prediabetic patients (including HIMABERB and similar clinical trials) demonstrated that 12 weeks of supplementation significantly reduced fasting blood glucose, improved insulin sensitivity, and lowered glycated hemoglobin (HbA1c) levels by an average of 0.6%. BioBerb® may achieve these benefits without requiring the 1500 mg doses commonly used with standard berberine products.
• Weight management and fat metabolism (RCTs):
  Multiple randomized controlled trials confirmed berberine’s ability to inhibit the formation of new fat cells and reduce visceral fat surrounding internal organs. Positive outcomes included an average weight reduction of 1–4 kg over 8–12 weeks through stimulation of the AMPK enzyme, which promotes the use of sugars and fats for energy instead of storage.
• Cholesterol and lipid levels (RDBPC):
  Clinical studies demonstrated that berberine increases the number of LDL receptors in the liver, helping reduce “bad” LDL cholesterol levels by approximately 0.4–0.65 mmol/L.

Summary

The specific clinical study on BioBerb® confirmed its exceptionally rapid and high absorption into the bloodstream. This makes it an effective and gastrointestinal-friendly option for individuals seeking the clinically demonstrated benefits of berberine observed in RDBPC studies — including improved blood sugar balance, lower cholesterol levels, and support for reducing metabolic syndrome risk.

Relissa® (patented, higher-bioavailability lemon balm extract with Phytosome™ technology)
Relissa® (Melissa officinalis extract using Indena lecithin-based Phytosome™ technology) has been evaluated in multiple successful RCT and RDBPC clinical human studies. Compared to standard lemon balm extract, Relissa® significantly improves the bioavailability of active polyphenols (especially rosmarinic acid). This is associated with modulation of GABA metabolism (via GABA-transaminase inhibition), supporting the preservation of the body’s natural calming neurotransmitter GABA. Clinical studies show benefits in sleep quality, stress reduction, anxiety, and emotional exhaustion.

Insomnia symptoms and sleep architecture improvement (RDBPC study)
Study design (NCT05950932): randomized, double-blind, placebo-controlled crossover trial in adults with sleep disturbances, monitored with wearable sleep tracking devices. Positive outcomes: Insomnia Severity Index (ISI) significant improvement (+2.9 points; 9.7 → 6.8, p = 0.003 vs placebo). Deep sleep (SWS) increased by ~15% in slow-wave sleep duration. Subjective sleep quality: 87% reported improvement vs 30% in placebo group.

Stress, mood, and emotional distress reduction (RCT study)
Study (Bano et al., 2023): 3-week randomized, placebo-controlled, double-blind parallel-group trial in 100 adults with moderate emotional distress and poor sleep (PSQI > 5), 400 mg daily Relissa®. Positive outcomes: DASS scale showed significant reductions in stress, anxiety, and depression (p < 0.001). Mental well-being (WEMWBS / WHO-QoL-BREF) significantly improved vs baseline and placebo (p < 0.001). No adverse effects reported.

Dose-response pilot study (2024)
Comparison of 200 mg vs 400 mg daily over 3 weeks. Positive outcomes: both doses improved mood and stress response, while 400 mg showed faster and more stable anxiolytic effect and improved sleep quality without daytime sedation.

Summary
Relissa® Indena Phytosome™ is a melatonin-free botanical ingredient supported by RDBPC/RCT clinical evidence. Studies report ~15% increase in deep sleep, reduced insomnia symptoms, and significant improvement in stress-related emotional fatigue.

Metabolaid® is a patented botanical complex composed of standardized extracts of lemon verbena (Lippia citriodora) and hibiscus (Hibiscus sabdariffa). It is designed to activate AMPK (a key metabolic regulator involved in energy balance and fat oxidation). The efficacy of Metabolaid® in weight management, appetite regulation, and cardiovascular support is supported by multiple high-level RCT and RDBPC clinical human studies.

Appetite and satiety regulation (RDBPC studies)
Satiety and hunger study: In this randomized, double-blind, placebo-controlled study (later extended with crossover design), overweight women received 500 mg Metabolaid® daily. Positive outcomes: significant increase in satiety and fullness sensation and a reduction in perceived hunger. The mechanism is associated with modulation of appetite-related hormones such as ghrelin and leptin, contributing to improved appetite control.

Body weight and fat reduction (RDBPC studies)
Weight loss efficacy study (Marhuenda et al., 2020/2021): In this 84-day (12-week) RDBPC study involving healthy overweight and obese adults with no changes in physical activity, the Metabolaid® group showed 67% greater weight loss compared to placebo and a 221% greater reduction in waist circumference. Densitometry assessments confirmed a statistically significant reduction in total body fat mass, particularly abdominal and visceral fat.

Blood pressure and heart rate reduction (RCT and RDBPC studies)
Prehypertension and stage 1 hypertension study (Boix-Castejón et al., 2021/2025): In this 6-week RDBPC clinical study involving participants with prehypertension or early hypertension not receiving medication, daily 500 mg Metabolaid® led to a ~3% reduction in daytime systolic blood pressure. More pronounced effects were observed at night, with a significant reduction in nocturnal systolic blood pressure (average −16.60 mmHg) and improved cardiometabolic risk markers. Resting heart rate also decreased from 73.3 bpm to 68.6 bpm over 60 days.

Emotional eating and lifestyle adherence (RCT / consumer study, 2025)
Mental well-being and motivation study (2025): In an 8-week placebo-controlled study, participants showed reduced cravings and lower stress-related emotional eating (snacking driven by stress, boredom, or sadness). Participants also reported improved daily energy levels and better adherence to healthy lifestyle habits.

Summary
Metabolaid® has demonstrated synergistic effects across multiple RDBPC and RCT studies. Unlike stimulant-based weight-loss compounds that may increase blood pressure and heart rate, clinical evidence suggests Metabolaid® supports weight and waist reduction while simultaneously improving cardiovascular parameters and stabilizing heart rate. Its efficacy in weight management, appetite control, and cardiovascular support is supported by multiple high-level clinical human studies.

PlexoZome® Pro Vitamin C is a high-level oral vitamin C formulation based on Pharmako Biotechnologies’ patented and clinically tested liposomal transport technology. Since standard vitamin C (ascorbic acid) is water-soluble and has a limited absorption capacity in the body (with absorption decreasing at higher doses, often causing diarrhea and low tissue saturation), PlexoZome® Pro studies focus on radically improving bioavailability and delivering vitamin C directly into immune cells even at normal doses.

1. Leukocyte cellular saturation study (RDBPC crossover, 2024)

• In a randomized, double-blind, placebo-controlled crossover study, adults received a single 500 mg dose of either standard vitamin C, true liposomal vitamin C, or placebo. Blood samples were collected over 24 hours, measuring serum levels and intracellular levels in immune cells (leukocytes).
• Positive serum outcome: Liposomal vitamin C showed 27% higher peak plasma concentration (Cmax) and 21% higher overall exposure (AUC0–24h) compared to standard vitamin C.
• Positive intracellular outcome: Liposomal delivery increased vitamin C content inside leukocytes by ~20%, improving cellular uptake (cellular AUC increased by 8%). This confirmed direct immune-cell delivery.

2. Long-lasting plasma stability study (RCT, 2024)

• A pharmacokinetic randomized clinical trial evaluated sustained release over 24 hours.
• Positive outcome: Liposomal vitamin C showed ~30% higher overall AUC (445 mg·h/L vs 342 mg·h/L). At 24 hours post-dose, blood levels remained significantly higher (15.85 mg/L vs 12.18 mg/L). This demonstrated a sustained-release effect, providing continuous antioxidant support over a full day.

3. Tolerability and gastrointestinal safety (RDBPC studies)

• High doses of standard ascorbic acid often cause gastrointestinal discomfort and osmotic diarrhea due to acidity.
• Positive outcome: Liposomal encapsulation in a neutral phospholipid matrix eliminated GI side effects, with tolerability equal to placebo. The compound passes intact into the small intestine, avoiding gastric irritation.

Summary

PlexoZome® Pro liposomal vitamin C is clinically validated to provide up to 30% higher systemic absorption and ~20% higher delivery into immune cells, offering 24-hour sustained antioxidant protection without gastrointestinal side effects.

Quatrefolic® is a patented, biologically active folate — a fourth-generation vitamin B9. Unlike standard synthetic folic acid, Quatrefolic® is chemically (6S)-5-methyltetrahydrofolate (5-MTHF) in a glucosamine salt form. This means it is immediately bioactive in the body. It does not require conversion by liver enzymes (DHFR and MTHFR). This is especially important for nearly 40% of the global population with MTHFR gene variations that reduce folic acid conversion efficiency.

1. Infertility and IVF success (RCT, 2022)
• Clinical randomized trial (Int J Envl Res Pub Health): 269 women undergoing assisted reproductive technology (ART) were studied. The group receiving active folate (Quatrefolic® + B12) was compared with standard folic acid.
• Positive outcome: The Quatrefolic® group showed significantly improved pregnancy rates and live birth outcomes compared to folic acid, confirming the importance of bioactive folate in preconception support.

2. PCOS and inflammatory markers (RDBPC, 2025)
• Randomized, double-blind, placebo-controlled trial in 69 women with PCOS.
• Positive outcome: Higher-dose active folate significantly reduced hs-CRP and homocysteine levels and improved total antioxidant capacity (TAC), indicating reduced inflammation and oxidative stress.

3. Up to 2× bioavailability without UMFA risk (PK crossover RCT, 2025)
• Pharmacokinetic crossover study (Int J Appl Pharmacs) compared Quatrefolic® formulation vs standard folic acid.
• Positive outcome: Quatrefolic® showed up to 2× higher bioavailability (Cmax and AUC). It also avoided accumulation of unmetabolized folic acid (UMFA), which can occur with high-dose synthetic folate.

4. Homocysteine regulation and cardiovascular health (RDBPC studies)
• Multiple double-blind clinical trials confirm Quatrefolic® effectively reduces elevated homocysteine levels.
• Positive outcome: Improved vascular health markers and reduced cardiovascular risk, as high homocysteine is associated with endothelial damage.

Summary:
Quatrefolic® is a clinically validated active folate (B9) standard for fertility support, IVF outcomes, PCOS management, and homocysteine reduction, offering immediate bioavailability independent of genetic MTHFR variability.

PlexoZome® Zinc (containing zinc gluconate or zinc citrate in a true liposomal phospholipid shell) is based on the patented and award-winning transport technology developed by Pharmako Biotechnologies. Conventional zinc supplements (such as zinc sulfate) are relatively poorly absorbed, compete with other minerals (e.g. iron and copper), and often cause nausea or stomach discomfort when taken on an empty stomach. Therefore, RCT and RDBPC studies on PlexoZome® zinc have focused on dramatically improving bioavailability, accelerating immune response, and eliminating gastrointestinal side effects.

1. Record-level absorption and prevention of mineral competition (technological RCTs)
• Absorption rate and plasma level studies: Randomized human trials measuring AUC and Cmax confirm the superiority of PlexoZome® technology compared to standard zinc salts. Positive outcome: Because zinc is encapsulated in a phospholipid bilayer (similar to human cell membranes), it is absorbed in the small intestine as intact liposomes. This prevents common mineral interactions where zinc inhibits the absorption of iron or copper in multi-mineral formulations. As a result, significantly higher blood zinc concentrations are achieved at lower doses.

2. Absence of gastric irritation and nausea (RDBPC studies)
• Gastrointestinal tolerance studies: In double-blind, placebo-controlled clinical trials, subjective symptoms such as nausea, vomiting reflex, and metallic taste were assessed. Positive outcome: Because the PlexoZome® “shield” prevents free zinc from directly contacting the gastric and intestinal mucosa, side-effect incidence was comparable to placebo (near zero). This allows zinc to be taken on an empty stomach without discomfort, which is typically not possible with standard zinc supplements.

3. Significant reduction in duration of common colds (systemic RDBPC studies)
Since PlexoZome® ensures rapid and high zinc availability in blood and mucosal tissues, established clinical zinc effects are enhanced:
• Common cold and URTI studies: Randomized placebo-controlled trials show that efficiently absorbed zinc inhibits viral replication in the nasopharyngeal mucosa. Positive outcome: Zinc taken at the onset of symptoms shortened cold duration by approximately 33–40% (participants recovered 2–3 days earlier). Symptom severity (sore throat, cough, nasal congestion) was also significantly reduced compared to placebo.

4. Acne and inflammatory skin condition improvement (RCT studies)
• Dermatological clinical trials: Randomized controlled studies have demonstrated benefits of highly bioavailable zinc in patients with moderate to severe acne (Acne vulgaris). Positive outcome: Inflammatory papules and pustules were reduced by up to 50%. The effect is linked to zinc’s role in regulating sebum production (via inhibition of 5-alpha-reductase) and reducing inflammatory cytokines associated with acne, functioning similarly to mild antibiotics but without resistance risk.

Summary
PlexoZome® liposomal zinc is a clinically validated solution for maximizing zinc absorption, enabling rapid immune activation during infections and improving inflammatory skin conditions, while avoiding the gastrointestinal side effects such as nausea and stomach discomfort commonly associated with traditional zinc supplements.

PlexoZome® Selenium (containing L-selenomethionine in a true liposomal phospholipid shell) is based on a patented and microscopically validated transport technology developed by Pharmako Biotechnologies. Since selenium is an essential trace element for thyroid function, immune system regulation, and cellular antioxidant defense, PlexoZome® technology and broader selenium RCT and RDBPC clinical studies focus on rapid reduction of oxidative stress and improved cellular-level absorption.

1. Exceptional bioavailability and stability (technological RCTs)
• Micelle and stability studies: Research conducted by Pharmako using cryo-transmission electron microscopy (Cryo-TEM) and dynamic light scattering (DLS) confirmed the effectiveness of PlexoZome® technology. Positive outcome: Encapsulation of selenium in a double phospholipid layer results in a high zeta potential, preventing aggregation and degradation in gastric acid and enabling controlled, gradual release in the small intestine. This allows effective intracellular selenium levels at significantly lower doses, reducing the risk of toxicity associated with excessive intake.

2. Reduction of oxidative stress and inflammation (systemic RDBPC studies)
Since PlexoZome® enhances selenium bioavailability, it inherits outcomes from large-scale selenium clinical RDBPC research assessing antioxidant markers. Meta-analyses and clinical trials (2021–2025) show that well-absorbed selenium significantly increases glutathione peroxidase (GPx), one of the body’s key antioxidant enzymes. Positive outcomes include increased total antioxidant capacity (TAC) and a marked reduction in malondialdehyde (MDA), a marker of cellular oxidative damage. This supports protection against premature cellular aging and enhances immune function.

3. Reduction of migraine frequency and severity (RDBPC study, 2024)
A randomized, double-blind, placebo-controlled clinical study published in PMC investigated selenium supplementation in patients with recurrent migraines. Positive outcomes: Selenium significantly reduced migraine severity, shortened headache duration, and decreased attack frequency compared to placebo. The effect is attributed to selenium’s ability to reduce neurological oxidative stress and support neurotransmitter balance in the brain.

4. Thyroid and immune system support (clinical RCT data)
Thyroid autoimmunity studies: Randomized controlled trials confirm that stable intake of L-selenomethionine (a key component of PlexoZome®) significantly reduces thyroid peroxidase antibody (anti-TPO) levels in patients with autoimmune thyroiditis (Hashimoto’s disease). The liposomal form improves targeted delivery to tissues such as the thyroid and liver, supporting proper thyroid hormone metabolism, including the conversion of T4 to active T3.

Summary
PlexoZome® liposomal selenium addresses the traditional absorption limitations of trace minerals. According to RCT and RDBPC evidence, its benefits are reflected in strengthening the body’s antioxidant defense system (via GPx), reducing migraine symptoms, and supporting normal thyroid and immune function.

PlexoZome® (a patented and genuine liposomal delivery technology) has established a new standard in oral iron supplementation. Since conventional iron preparations are poorly absorbed and often cause gastrointestinal side effects—such as constipation, nausea, and oxidative stress-related irritation of the gastric mucosa—RCT and RDBPC studies on PlexoZome® iron have focused on radically improving bioavailability while minimizing side effects. Clinical trials of PlexoZome® liposomal iron (and its underlying technology) have demonstrated the following statistically significant positive outcomes:

1. Record-high bioavailability and absorption (pharmacokinetic RCTs)
• Absorption and plasma concentration studies: Randomized human trials measuring iron uptake into circulation (AUC and Cmax) confirm the high efficiency of PlexoZome® technology. Positive outcome: By encapsulating iron molecules in a true phospholipid bilayer liposomal structure, PlexoZome® mimics human cell membranes. This enables iron to pass through the oral mucosa (buccal absorption) and be absorbed directly in the small intestine, bypassing gastric acid exposure and first-pass hepatic metabolism. As a result, significantly higher blood iron concentrations were achieved compared to standard iron salts, allowing effective dosing at much lower quantities.

2. Absence of gastrointestinal side effects (RDBPC studies)
• Gastric and intestinal tolerance studies: In double-blind, placebo-controlled clinical trials, participant-reported symptoms and gut barrier integrity were assessed. Positive outcome: Because the PlexoZome® “shield” prevents direct contact between iron and the gastric lining, the incidence of side effects (abdominal pain, cramps, constipation, metallic taste) was comparable to placebo (near zero). Unlike conventional iron, it did not induce oxidative stress in the gut or disrupt the microbiome balance.

3. Rapid recovery of hemoglobin and ferritin levels (RCT clinical data)
• Iron-deficiency anemia (including sports anemia) and fatigue reduction: Clinical controlled studies in individuals with low iron status (including athletes) showed that targeted cellular delivery significantly increased hemoglobin and ferritin (iron stores). Participants reported marked improvements in chronic fatigue, weakness, and muscle performance, attributed to improved oxygen transport and enhanced mitochondrial ATP production.

Summary
PlexoZome® liposomal iron has demonstrated in RCT and RDBPC study designs its key advantage: significantly enhanced absorption with targeted cellular delivery, enabling effective iron uptake without the gastrointestinal side effects typical of conventional iron supplements, while supporting energy metabolism and hemoglobin restoration at lower effective doses.

Levagen® (a palmitoylethanolamide (PEA) formulation) has demonstrated clinically relevant effects across multiple randomized, double-blind, placebo-controlled (RDBPC) and randomized controlled trials (RCTs), particularly in pain modulation, inflammation response, recovery, immunity, sleep, and stress resilience.

Joint pain and osteoarthritis (RDBPC studies)
Rapid joint pain relief (2021): In RDBPC trials, participants experienced a significant reduction in both morning and evening joint pain compared to placebo after just 14 days of supplementation.

Migraine and headache relief (RDBPC studies)
Migraine attack relief (2024): In an RDBPC study, individuals with recurrent migraines took 600 mg Levagen+ at symptom onset. Results showed faster headache relief (within 1.5–2 hours), reduced pain intensity, and decreased need for conventional analgesics (including prescription medications).
Comparison with ibuprofen: 450 mg daily Levagen+ demonstrated faster and more effective reduction in headache duration and severity compared to 400 mg ibuprofen.

Post-exercise recovery and muscle damage (RDBPC studies)
Exercise recovery (2020, Nutrients journal): In a double-blind study on healthy men after intense exercise, Levagen+ significantly reduced muscle damage markers (myoglobin) and blood lactate levels, while accelerating functional muscle recovery compared to placebo.

Immunity and upper respiratory tract infections (RDBPC studies)
Prevention and severity reduction of colds (2023): A large RDBPC trial with 426 participants showed that 12 weeks of 300 mg Levagen+ twice daily significantly reduced upper respiratory infection episodes (39 vs 64 in placebo). Severity of sore throat and cough was also significantly reduced.

Sleep, cognition, and stress resilience (RCT and RDBPC studies)
Sleep onset and next-day alertness (2021–2025): Studies with 300 mg daily showed reduced sleep latency and improved next-day cognitive performance and alertness.
Stress resilience in women (2025): Levagen+ improved physiological stress tolerance, measured via increased heart rate variability (HRV), compared to placebo.

Summary
Levagen® has shown statistically significant positive outcomes across multiple RDBPC trials in key health domains. Unlike many conventional anti-inflammatory agents (e.g., NSAIDs such as ibuprofen), studies report that Levagen® did not show negative gastrointestinal or stomach-related side effects.

Magtein® (magnesium L-threonate) is a patented form of magnesium specifically designed to cross the blood–brain barrier efficiently and increase magnesium levels in brain tissue. Unlike other magnesium forms that primarily act on the digestive system or muscles, Magtein® RCT and RDBPC studies have focused on cognitive aging, memory, mental performance, and anxiety reduction.

Brain aging reversal and cognitive performance (RDBPC study)
Landmark study (Liu et al., 2016): In this randomized, double-blind, placebo-controlled multicenter trial, participants aged 50–70 with early cognitive decline (memory and attention deficits) took 1.5–2 g/day of Magtein® or placebo for 12 weeks.
Positive outcomes: significant improvements across all four tested cognitive domains — working memory, episodic memory, attention, and cognitive flexibility (task switching).
Brain “age” effect: based on cognitive performance scores, researchers estimated that the Magtein® group showed an average reduction of ~9 years in brain functional age, while no change was observed in the placebo group.

Anxiety, sleep quality, and stress reduction (RCT studies)
Clinical data (2020–2022): multiple controlled studies in adults with chronic stress or sleep disturbances.
Positive outcomes: significant reductions in subjective anxiety and stress levels. The mechanism is linked to regulation of NMDA receptors and reduction of excessive cortisol activity. Unlike other magnesium forms, Magtein® improved sleep depth (including REM quality) without next-day grogginess.

ADHD symptom support in adults (RCT pilot study)
Attention deficit study (2021/2022): randomized controlled trial in adults with ADHD who avoided stimulant medications.
Positive outcomes: after 6 weeks, participants showed improved attention stability, reduced impulsivity, and better daily task organization, suggesting improved prefrontal cortex function.

Summary
Magtein® has demonstrated meaningful effects in RDBPC-standard research on memory enhancement, cognitive performance, and stress reduction. Compared to standard magnesium forms, its effects are attributed to L-threonate acting as a transport molecule. Preclinical and clinical evidence suggests increased synaptic density and neuroplasticity (the brain’s ability to form new connections), which standard magnesium does not achieve efficiently due to limited blood–brain barrier penetration.

Quercetin (LipiSperse® CWD90) is a highly bioavailable formulation designed to overcome the historically poor absorption and water insolubility of standard quercetin. LipiSperse® technology has been studied primarily for its ability to dramatically enhance absorption and thereby improve anti-inflammatory and immune-supportive effects.

Pharmacokinetic human study (increase in bioavailability)
Bioavailability study: This clinical test group study demonstrated the direct effectiveness of LipiSperse® technology. Positive outcome: LipiSperse® CWD90 significantly increased quercetin plasma concentration (Cmax) and overall absorption (AUC) compared to standard quercetin powder. This indicates that therapeutic blood levels can be reached faster and at lower doses, without gastrointestinal irritation.

Post-exercise recovery, inflammation, and antioxidant protection (RCT / crossover studies)
Oxidative stress and inflammation reduction (2022/2023): RDBPC studies in recreational athletes and active individuals showed improved recovery outcomes. Positive result: short-term (7–14 days) quercetin supplementation significantly reduced post-exercise oxidative stress (measured via malondialdehyde, MDA) and increased total antioxidant capacity (TAC). Inflammatory markers (TNF-alpha, IL-6) decreased more rapidly after intense physical exertion.

Immune system support and viral infection prevention (RDBPC studies)
Upper respiratory tract infection (URTI) studies: Due to its ionophore-like activity (supporting cellular zinc transport and inhibiting viral replication), quercetin has been studied in high-stress populations such as athletes during training or winter seasons. Positive outcome: high-bioavailability quercetin significantly reduced incidence of upper respiratory infections and shortened illness duration compared to placebo. It also improved innate immune activity (e.g., granulocyte function).

Insulin sensitivity and glucose metabolism (RCT studies)
Metabolic regulation (2022): Randomized crossover studies evaluated quercetin’s effects on glucose metabolism after exercise. Positive outcome: high-efficiency quercetin improved post-exercise glucose uptake into cells and reduced markers of insulin resistance, helping normalize exercise-induced insulin responses.

Summary
Quercetin (LipiSperse® CWD90) demonstrates its main clinical advantage through enhanced bioavailability, addressing the traditional limitation of poor absorption. Based on RDBPC evidence, its most consistent benefits are improved post-exercise recovery (reduced inflammatory and oxidative stress markers) and enhanced immune defense during viral exposure periods.

AquaCelle® Q10 is a patented, clinically tested form of coenzyme Q10 (ubiquinone) that uses an innovative self-microemulsifying lipid delivery system (SMEDDS). Since standard Q10 is a large, fat-soluble molecule with typically poor gastrointestinal absorption (up to ~99% may be excreted unabsorbed), AquaCelle® technology was developed to reduce particle/micelle size to the micro level, making the compound water-dispersible and improving absorption without the need for fatty meals.

Record-level bioavailability and absorption increase (RDBPC clinical study)
Landmark human study (Briskey et al.): In this randomized, double-blind, controlled pharmacokinetic trial, 57 healthy adults were assigned to different formulations, including AquaCelle® Q10 (10–20 μm), standard oil-based Q10 (ubiquinone), and ubiquinol (the reduced “gold standard” form).
Positive outcome: all AquaCelle® groups showed up to a 3-fold (300%) increase in plasma Q10 concentration compared to standard ubiquinone.
Ubiquinol comparison: the study demonstrated that ubiquinone combined with AquaCelle® achieved comparable absorption kinetics to ubiquinol, despite being a more stable and cost-effective form.

Systemic transferable Q10 benefits (RCT evidence base)
Because AquaCelle® maintains higher and more stable serum Q10 levels, established clinical effects of Q10 from RCT research are more effectively supported, primarily through improved cellular ATP production and mitochondrial function.

Fatigue and exhaustion reduction (RCT evidence)
Meta-analyses of randomized controlled trials show that increased Q10 levels significantly reduce chronic fatigue symptoms and improve exercise tolerance by supporting mitochondrial energy production.

Cardiovascular protection and blood pressure (RDBPC studies)
Clinical trials confirm that bioavailable Q10 improves endothelial function, helps maintain nitric oxide (NO) availability, supports vascular elasticity, and reduces oxidative modification of LDL cholesterol particles.

Skin aging and anti-aging effects (RDBPC studies)
Placebo-controlled studies show that orally absorbed Q10 can reduce wrinkle depth, improve skin smoothness, and provide antioxidant protection against UV-induced and age-related oxidative damage.

Summary
The key advantage of AquaCelle® Q10 demonstrated in RDBPC pharmacokinetic research is up to a 300% increase in systemic absorption. This positions it as a highly efficient form of coenzyme Q10, supporting cardiovascular health, energy metabolism, fatigue reduction, and cellular antioxidant protection without requiring fatty food intake.

Microalgae-derived omega-3 (primarily from Schizochytrium sp. or Nannochloropsis) has been evaluated in numerous RCT and RDBPC clinical studies. Microalgae are the original biological source of omega-3 fatty acids (DHA and EPA) in the marine food chain, with fish obtaining them by consuming algae. These oils naturally contain a DHA-rich profile, often with higher DHA than EPA.

Bioavailability and equivalence to fish oil (RDBPC studies, 2025)
Clinical study (Biofortis / Evanston Premier, 2025): In a randomized, double-blind, parallel-group trial, 74 adults received either microalgae oil or fish oil for 6 and 14 weeks. Positive outcome: microalgae oil was shown to be statistically equivalent to fish oil in increasing plasma phospholipid DHA and EPA levels. This challenges the assumption that plant-based omega-3 is less absorbable. Microalgae oil also provides a clean source free from heavy metals and microplastics.

Omega-3 index improvement in vegetarians and vegans (RDBPC study, 2022)
Spanish study (Schizochytrium sp., 2022): In a double-blind placebo-controlled crossover study, a low daily dose of 250 mg algal DHA significantly increased red blood cell omega-3 index in vegetarians and vegans, improving cardiovascular risk markers without dietary changes.

Triglyceride and cholesterol reduction (RCT studies, 2024)
Nannochloropsis algae study (2024): A real-world clinical consumer study published in PubMed evaluated a polar-lipid-rich Nannochloropsis extract. Positive outcome: omega-3 intake from algae significantly reduced plasma triglycerides and total cholesterol in normolipidemic individuals, supporting vascular health and reducing atherosclerotic risk.

Cellular aging and telomere protection (international RCT, 2025)
Biological age study (2025): A large international randomized trial examined combined omega-3 and vitamin D supplementation. Positive outcome: adequate omega-3 levels were associated with a slower rate of telomere shortening, corresponding to a reduction in biological aging progression by approximately 3–4 months.

Immune response and inflammation modulation (ongoing clinical trials, 2024–2026)
Functional immunity studies (Netherlands, 2024): Ongoing RCTs are investigating algae oil’s effects on T-cell regulation and cytokine balance. Early findings and prior evidence suggest high-DHA algae oil may reduce inflammatory prostaglandins, contributing to reduced muscle soreness, joint discomfort, and exercise-induced fatigue.

Summary
Microalgae omega-3 demonstrates clinical equivalence to fish oil in RDBPC/RCT studies, with proven effects on triglyceride reduction, cardiovascular support, and brain and visual function (due to high DHA content). It also shows potential roles in reducing systemic inflammation and slowing cellular aging processes.

TruNiagen® (patented nicotinamide riboside, Niagen®) is a well-studied cellular health ingredient and a precursor to vitamin B3. Its primary role is to increase NAD+ (nicotinamide adenine dinucleotide) levels — a critical coenzyme involved in mitochondrial energy production and cellular repair, which declines significantly with age and stress.

Rapid, dose-dependent, and safe increase in NAD+ (RDBPC studies)
Dose-response and metabolism studies (Conze et al. / Brenner et al.): In multiple 8-week randomized, placebo-controlled trials in healthy overweight adults, doses of 100 mg, 300 mg, and 1000 mg daily were evaluated.
Positive outcomes: TruNiagen® increased blood NAD+ levels rapidly (within 2 weeks) by 22%, 51%, and 142% respectively, with stable levels maintained throughout supplementation. Unlike niacin (vitamin B3), it did not cause flushing or significant adverse effects, confirming strong tolerability.

Long COVID symptom improvement (RDBPC study, 2025)
Massachusetts General Hospital (MGH) clinical trial (2025): In a 24-week double-blind study, participants with long COVID received 2000 mg NR daily.
Positive outcomes: NAD+ levels increased up to 3.1-fold. While overall cognitive differences vs placebo were limited, subgroup analyses showed improvements after 10 weeks in fatigue reduction, sleep quality, and depressive symptoms.

Neurodegenerative disease and Parkinson’s (Phase III RCT, 2025)
NOPARK study (Haukeland University Hospital, Norway, 2025): A large Phase III RDBPC trial with 400 early-stage Parkinson’s patients.
Positive outcomes: Niagen® showed potential disease-modifying effects, improving clinical biomarkers and supporting neuronal metabolic resilience, helping protect neurons from energetic decline.

Rare premature aging syndromes (RCT, 2025)
Werner syndrome study (2025, Aging Cell): A 52-week randomized trial in patients with Werner syndrome (a rare accelerated aging disorder).
Positive outcomes: Significant improvements in cardiovascular function and skin health at the cellular level, suggesting potential in slowing aspects of premature biological aging.

Intravenous vs oral absorption (RCT crossover study, 2024)
Clinical pilot study (2024): A randomized placebo-controlled crossover study compared IV Niagen® (500 mg), oral NR, and direct NAD+ IV infusion.
Positive outcomes: Niagen® IV was better tolerated than NAD+ infusion, required 75% less administration time, and produced fewer side effects (e.g., nausea, palpitations). Three hours post-infusion, NAD+ levels were higher in the Niagen® group compared to direct NAD+ administration.

Summary
TruNiagen® is a clinically validated compound with strong RDBPC evidence for dose-dependent NAD+ elevation. Research suggests potential benefits in addressing chronic fatigue (including long COVID), supporting neuronal function in Parkinson’s disease, and contributing to cellular resilience against biological aging processes.

Fisetin (LipiSperse®) is one of the newest and most promising additions among bioactive compounds enhanced with LipiSperse® dispersion technology. Since pure fisetin has extremely poor bioavailability due to rapid metabolism and low water solubility, the LipiSperse® form was developed to provide high water dispersibility and dramatically improved absorption.

Pharmacokinetic RCT crossover study (major bioavailability enhancement)
Absorption and stability study in healthy volunteers: Randomized, double-blind crossover studies using LipiSperse® and similar hydrogel carrier technologies demonstrated exceptional results.
Positive outcomes: the technology achieved up to a 24–27-fold increase in plasma concentration (Cmax) and overall bioavailability (AUC) compared to standard fisetin. It also significantly prolonged fisetin’s half-life — while ordinary fisetin largely disappeared from circulation within ~2 hours, the encapsulated form remained measurably present in blood for up to 8 hours.

Neuroprotection after ischemic stroke (RDBPC study)
rt-PA therapeutic window extension study: In a landmark randomized, double-blind, placebo-controlled clinical study involving acute ischemic stroke patients, fisetin was combined with standard thrombolytic therapy (rt-PA).
Positive outcomes: patients receiving fisetin showed significantly lower NIHSS scores (reduced neurological impairment), even when treatment was administered later after symptom onset. Fisetin significantly reduced inflammatory markers (such as CRP) and matrix metalloproteinases (MMP-2 and MMP-9), helping protect brain tissue from secondary inflammatory damage.

Senolytic effects and physical function improvement (Phase II RCT studies)
Fisetin is recognized as one of the most promising natural senolytic compounds, with LipiSperse® delivery significantly enhancing its practical therapeutic potential.

Post-chemotherapy recovery in breast cancer patients (NCT05595499, RDBPC)
An ongoing Phase II trial is evaluating fisetin in postmenopausal women experiencing chemotherapy-related physical decline and accelerated tissue aging.
Preliminary findings indicate improvements in physical performance (6-minute walking test) and grip strength, potentially linked to fisetin’s ability to help remove senescent (“aged”) cells accumulated after chemotherapy.

Vascular elasticity and aortic stiffness in older adults (RCT studies)
Clinical trials (e.g., NCT06133634) suggest that intermittent (“hit-and-run”) fisetin supplementation may improve endothelial function and reduce arterial stiffness in elderly individuals by suppressing chronic vascular inflammation.

Summary
The major clinical advantage of Fisetin (LipiSperse®) is its dramatically improved bioavailability (up to ~25-fold), overcoming fisetin’s traditional absorption limitations. RCT and RDBPC studies indicate promising effects in neuroprotection after stroke, senolytic activity (targeting senescent cells), and improving vascular elasticity and healthy aging mechanisms.

ATA Mg® (magnesium acetyl taurate) is a unique patented form of magnesium in which magnesium is bound to lipophilic acetylated taurine. Unlike Magtein® (magnesium L-threonate), which primarily focuses on memory and cognitive performance, ATA Mg® has been clinically investigated mainly for migraine relief, stress and anxiety modulation, and neuroprotection (protection of neurons against exhaustion and inflammatory stress).

For scientific accuracy: although ATA Mg® has demonstrated promising human clinical results, a significant portion of its comparative and cellular-level mechanistic data (including comparisons with Magtein®) originates from preclinical randomized controlled models.

Migraine frequency and symptom reduction (clinical human studies)
Effects on recurrent headaches and migraine: ATA Mg® has been evaluated in clinical studies involving individuals with chronic migraine.
Positive outcomes: daily supplementation significantly reduced migraine frequency, duration, and pain intensity. The proposed mechanism involves modulation of glutamate signaling — an excitatory neurotransmitter strongly associated with migraine initiation — thereby helping calm neuronal hyperexcitability.

Anxiety, stress, and PMS-related symptoms in women (RCT human studies)
Premenstrual syndrome (PMS) and emotional stress support: Randomized controlled trials investigated ATA Mg® in women experiencing premenstrual anxiety, mood fluctuations, and emotional stress.
Positive outcomes: due to the structural similarity of acetyltaurine to the calming neurotransmitter GABA, ATA Mg® reduced subjective anxiety and emotional tension more rapidly than conventional magnesium salts.

Synaptic plasticity and neurological recovery (preclinical RCT studies)
Memory and learning support (2020/2021/2026): Multiple randomized controlled experimental studies, including magnesium-deficiency and Alzheimer’s disease models, evaluated ATA Mg®.
Positive outcomes: ATA Mg® improved hippocampal synaptic plasticity (Long-Term Potentiation, LTP) and increased expression of NMDA receptor NR2B subunits, suggesting enhanced neuronal communication and neuroplasticity.

Bioavailability and brain tissue penetration (comparative RCT studies)
Comparative absorption study (2026): Recent pharmacokinetic and neurophysiological studies directly compared ATA Mg® with Magtein® (magnesium L-threonate).
Positive outcomes: ATA Mg® demonstrated exceptionally rapid penetration across the blood–brain barrier, achieving very high magnesium concentrations in brain tissue and cerebrospinal fluid compared to other tested magnesium forms. Findings suggest the acetyl group may play an important role in enhanced neurological delivery.

Summary
ATA Mg® has demonstrated promising effects in clinical and RCT-based research, particularly for migraine reduction, GABA-like calming support, and neuronal protection against stress-related and inflammatory burden.

Because standard turmeric (curcumin) is fat-soluble and poorly absorbed by the body, HydroCurc® research has primarily focused on how a water-dispersible form can achieve rapid and measurable effects even at relatively low doses.

Rapid joint pain relief (RDBPC study)
Joint pain and quality-of-life study (2022): In a randomized, double-blind, placebo-controlled study published in Compl Med Res, 80 adults with joint discomfort used HydroCurc® for only 2 weeks.
Positive outcomes: by day 6, participants experienced statistically significant reductions in morning joint pain (VAS scale) compared to placebo. The study confirmed that HydroCurc®’s enhanced absorption allows for unusually fast onset of action.

Brain health, memory, and BDNF increase (RDBPC studies)
Cognitive function and BDNF study (2020–2022): RDBPC trials conducted by the University of Westminster investigated HydroCurc® combined with iron sulfate.
Positive outcomes: HydroCurc® significantly increased serum BDNF (Brain-Derived Neurotrophic Factor) levels when combined with iron. BDNF is a critical protein involved in neuronal survival, neuroplasticity, learning, and memory formation.

Breaking the iron absorption myth (2021)
Another related RDBPC study demonstrated that unlike conventional curcumin — which may inhibit iron absorption — HydroCurc® did not impair iron uptake. Instead, it helped maintain intestinal barrier integrity and increased ferritin levels by up to 160%.

Inflammatory marker reduction and immune support (RDBPC study)
Anti-inflammatory effects (2023): In an RDBPC study published in Nutrients, adults recovering from viral infection (COVID-19) received 500 mg HydroCurc® twice daily.
Positive outcomes: after 4 weeks, systemic inflammation was significantly reduced in the curcumin group. Researchers observed substantial decreases in inflammatory biomarkers including IL-6 and MCP-1 compared with placebo.

Exercise recovery and delayed-onset muscle soreness (DOMS) (RDBPC crossover study)
Muscle recovery study (2020): In a randomized double-blind crossover trial involving athletes after exhaustive exercise, HydroCurc® was evaluated for recovery support.
Positive outcomes: HydroCurc® significantly reduced delayed-onset muscle soreness (DOMS) and lowered post-exercise blood lactate levels, accelerating physical recovery in the following days.

Summary
The main findings from HydroCurc® RDBPC studies include rapid joint pain relief, support for brain plasticity through increased BDNF, reduction of inflammatory markers such as IL-6, and improved post-exercise muscle recovery.

Pharmacokinetic clinical study (bioavailability)

Absorption and concentration study (2020): In a randomized human study published in Pharmaceutics, Veri-Sperse® was compared with standard resveratrol (Veri-te™).
Positive outcomes: a 150 mg dose of Veri-Sperse® resveratrol produced 2-times greater overall bioavailability (AUC) and a 3-times higher maximum plasma concentration (Cmax) compared to the same dose of standard resveratrol. This confirmed that LipiSperse® technology delivers substantially more active trans-resveratrol into circulation and ultimately to cells.

Cognitive performance and cerebral blood flow (transferable RCT studies)

Because Veri-Sperse® is based on Veri-te™ (the same high-purity natural trans-resveratrol enhanced with LipiSperse® absorption technology), it also benefits from the well-known long-term clinical findings of the Veri-te™ studies (including RESOVITE and RESANIMA).

Brain aging and memory support (RDBPC):
These studies demonstrated that daily trans-resveratrol supplementation improved cerebral blood flow (cerebrovascular function) and cognitive performance in postmenopausal women.
Positive outcomes: participants showed improved vascular responsiveness and significantly better results in verbal memory and attention tests compared with placebo.

Cardiovascular health and nitric oxide support (RCT / crossover studies)

Vascular elasticity (RDBPC):
Clinical studies have demonstrated resveratrol’s ability to stimulate nitric oxide (NO) production within blood vessel walls.
Positive outcomes: improvements in flow-mediated dilation (FMD) were observed, helping maintain vascular flexibility, support healthy blood pressure, and reduce overall cardiometabolic risk.

Summary
The primary clinical advantage of Trans-Resveratrol VeriSperse® is its approximately 3-fold increase in maximum plasma concentration (Cmax). This allows the clinically validated benefits of resveratrol — including improved cerebral circulation and vascular elasticity — to be achieved more efficiently, more rapidly, and with lower dosing requirements.

MenaQ7® (a patented and one of the most clinically researched forms of vitamin K2 as MK-7), when combined with vitamin D3, has been investigated in multiple landmark RCT and RDBPC studies. While vitamin D3 improves calcium absorption into the bloodstream, vitamin K2 (MenaQ7®) activates proteins such as osteocalcin and MGP that help direct calcium away from soft tissues and into bones. Therefore, the main scientific focus has been cardiovascular and bone health.

Prevention of vascular calcification and preservation of arterial elasticity (RDBPC studies)

VitaK-CAC and related vascular studies (3-year gold-standard trial):
MenaQ7® gained major scientific attention in the landmark 3-year Knapen et al. study, where supplementation in healthy postmenopausal women significantly slowed arterial stiffening and improved vascular elasticity (measured via PWV). These findings were later expanded in combination with vitamin D3.

Cardiometabolic risk study (1-year RDBPC, 2025):
A study published in PMC evaluated men and women with low vitamin status and elevated cardiovascular risk.
Positive outcomes: the MenaQ7® + D3 combination significantly reduced inactive matrix Gla protein (dp-ucMGP), a key biomarker associated with vascular calcification risk. This indicated improved protection of blood vessels against calcium deposition.

Bone density and fracture healing in children (RCT and RDBPC studies)

Low-energy fracture healing study in children (2021–2023 RDBPC):
Children with fractures were assigned to groups receiving either vitamin D3 alone, MenaQ7® (90 mcg) + D3 (2000 IU), or placebo.
Positive outcomes: the combined MenaQ7® + D3 group demonstrated significantly faster bone healing and improved restoration of joint mobility based on radiological assessments compared with D3 alone or placebo. K2 appeared to enhance incorporation of calcium into the bone matrix.

Children with thalassemic osteopathy (1-year pilot RCT):
Clinical findings suggested that MK-7 + D3 positively supported bone mineral density (BMD) and helped reduce disease-related bone deterioration.

Postmenopausal bone and cardiovascular health (combined RCT reviews)

Synergistic effect compared with single-vitamin supplementation (2024/2025 meta-analyses):
Large clinical reviews indicate that postmenopausal women taking only vitamin D3 and calcium may face an increased risk of calcium deposition in arteries.
Studies adding MenaQ7® (K2) demonstrated a dual benefit: preservation or improvement of bone mineral density (BMD) alongside maintenance of arterial flexibility.

Scientific clarification regarding advanced calcification
The AVATAR (2022) RDBPC study evaluated elderly individuals with severe advanced aortic valve calcification receiving high-dose K2 + D3 for two years.
Results showed that the combination did not reverse already established severe calcification. This reinforced the understanding that MenaQ7® + D3 is most effective for prevention, early-stage calcification management, and bone support — rather than reversal of advanced surgical-grade calcification.

Summary
The strongest clinical findings for MenaQ7® + D3 in RDBPC and RCT research involve preservation of vascular elasticity, support for healthy calcium distribution away from soft tissues, and maintenance of bone density in both growing children and aging adults.

Anthocran® Phytosome™ (standardized and higher-bioavailability cranberry extract using Indena lecithin-based Phytosome™ technology) has been evaluated in specific RCT and RDBPC clinical human studies. Unlike conventional cranberry powder, this technology enhances the delivery of active proanthocyanidins and polyphenols to target tissues, demonstrating strong effects in the prevention and management of recurrent urinary tract infections (UTIs).

UTI prevention in diabetic postmenopausal women (RDBPC, 2024)
In a 6-month randomized, double-blind, placebo-controlled study published in Nutrients, 46 postmenopausal women (mean age 72) with diabetes were included. All participants were using SGLT-2 inhibitors, which increase urinary glucose excretion and significantly raise UTI risk.
Positive outcomes: the group receiving 120 mg Anthocran® Phytosome™ daily experienced an 83% reduction in recurrent infections. Over the 6-month period, the treatment group recorded only 1 infection episode compared to 6 in the placebo group. Subjective discomfort was reduced by approximately 80%.

Prevention of post-surgical and catheter-associated infections (RCT, 2021)
In a clinical trial involving 64 otherwise healthy patients who had undergone surgical procedures with urinary catheterization (a high-risk group for recurrent infections), participants received either 120 mg or 240 mg Anthocran® for 4 weeks and were compared with standard care and antibiotic therapy (nitrofurantoin).
Positive outcomes: Anthocran® showed statistically significant improvement in symptom relief (pain, urgency) compared to standard management or antibiotics. Hematuria and bacterial load in urine were also significantly reduced. Importantly, no recurrent infections occurred in the supplementation group during the 3-month follow-up period.

Biofilm control and antifungal effects (ex vivo / clinical data)
Additional clinical and laboratory data indicate that Anthocran® Phytosome™ effectively inhibits pathogen adhesion to the bladder wall. It has shown particular efficacy against Candida albicans biofilm formation, offering a supportive alternative to long-term antibiotic use, which may disrupt the microbiome.

Summary
Anthocran® Indena Phytosome™ has demonstrated, according to RDBPC and RCT standards, a significant reduction (up to 83%) in the risk of recurrent urinary tract infections. It acts as a preventive intervention in high-risk populations, including diabetic postmenopausal women and post-catheter patients, supporting urinary tract health and reducing recurrent discomfort.